ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/omet12817ometendo-12817Research ArticleКЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИCLINICAL PRACTICE GUIDELINESПроект клинических рекомендаций «Синдром гипогонадизма у мужчин»Draft of Russian Clinical Practice Guidelines «Male hypogonadism»https://orcid.org/0000-0002-8175-7886ДедовИ. И.DedovI. I.

Дедов Иван Иванович - доктор медицинских наук, профессор, академик РАН; eLibrary SPIN: 5873-2280

Москва

Ivan I. Dedov - MD, PhD, Professor, academician of RAS; eLibrary SPIN: 5873-2280

dedov@endocrincentr.ruhttps://orcid.org/0000-0002-9717-9742МокрышеваН. Г.MokryshevaN. G.

Мокрышева Наталья Георгиевна - доктор медицинских наук, профессор; eLibrary SPIN: 5624-3875

Москва

Natalia G. Mokrysheva - MD, PhD, Professor; eLibrary SPIN: 5624-3875

https://orcid.org/0000-0002-5634-7877МельниченкоГ. А.MelnichenkoG. A.

Мельниченко Галина Афанасьевна - доктор медицинских наук, профессор; eLibrary SPIN: 8615-0038, академик РАН.

Москва

Galina A. Melnichenko - MD, PhD, Professor, academician of RAS; eLibrary SPIN: 8615-0038.

teofrast2000@mail.ruhttps://orcid.org/0000-0002-5386-4289РоживановР. В.RozhivanovR. V.

Роживанов Роман Викторович - доктор медицинских наук; eLibrary SPIN: 8052-3310.

117036, Москва, ул. Дм. Ульянова, д.11

Roman V. Rozhivanov - MD, PhD; eLibrary SPIN: 8052-3310.

11 Dm. Ulyanova street, 117036 Moscow

rrozhivanov@mail.ruhttps://orcid.org/0000-0003-4251-7545КамаловА. А.KamalovA. A.

Камалов Армаис Альбертович - доктор медицинских наук, профессор; eLibrary SPIN: 6609-5468.

Москва

Armais A. Kamalov - MD, PhD, Professor; eLibrary SPIN: 6609-5468

priemnaya@mc.msu.ruhttps://orcid.org/0000-0003-1316-5245МкртумянА. М.MkrtumyanА. M.

Мкртумян Ашот Мусаелович - доктор медицинских наук, профессор; Author ID: 513441; eLibrary SPIN: 1980-8700

Ashot M. Mkrtumyan - MD, PhD, Professor; Author ID: 513441; eLibrary SPIN: 1980-8700

vagrashot@mail.ruhttps://orcid.org/0000-0002-7755-7275ХалимовЮ. Ш.KhalimovYu. Sh.

Халимов Юрий Шакатович - доктор медицинских наук, профессор; eLibrary SPIN: 7315-6746.

Санкт-Петербург

Yurii Sh. Khalimov - MD, PhD, Professor; eLibrary SPIN: 7315-6746.

St. Petersburg

yushkha@gmail.comhttps://orcid.org/0000-0002-9574-105XВорохобинаН. В.VorokhobinaN. V.

Ворохобина Наталья Владимировна - доктор медицинских наук, профессор; eLibrary SPIN: 4062-6409.

Санкт-Петербург

Natalya V. Vorokhobina - MD, PhD, Professor; eLibrary SPIN: 4062-6409.

St. Petersburg

natvorokh@mail.ruНациональный медицинский исследовательский центр эндокринологии; Первый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)РоссияEndocrinology Research Centre; I.M. Sechenov First Moscow State Medical University (Sechenov University)Russian FederationНациональный медицинский исследовательский центр эндокринологииРоссияEndocrinology Research CentreRussian FederationМосковский государственный университет имени М.В. ЛомоносоваРоссияLomonosov Moscow State UniversityRussian FederationМосковский государственный медико-стоматологический университет имени А.И. ЕвдокимоваРоссияA.I. Yevdokimov Moscow State University of Medicine and DentistryRussian FederationВоенно-медицинская академия имени С.М. КироваРоссияS.M. Kirov Military Medical AcademyRussian FederationСеверо-Западный государственный медицинский университет имени И.И. МечниковаРоссияI.I. Mechnikov Northwestern State Medical UniversityRussian Federation202119022022184496507Copyright © Дедов И.И., Мокрышева Н.Г., Мельниченко Г.А., Роживанов Р.В., Камалов А.А., Мкртумян А.М., Халимов Ю.Ш., Ворохобина Н.В., 20222022Дедов И.И., Мокрышева Н.Г., Мельниченко Г.А., Роживанов Р.В., Камалов А.А., Мкртумян А.М., Халимов Ю.Ш., Ворохобина Н.В.Dedov I.I., Mokrysheva N.G., Melnichenko G.A., Rozhivanov R.V., Kamalov A.A., Mkrtumyan А.M., Khalimov Y.S., Vorokhobina N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/12817

Гипогонадизм у мужчин, определяемый как снижение уровня тестостерона в сыворотке крови в сочетании с характерными симптомами и/или признаками, может наблюдаться при патологических изменениях яичек и/или гипофиза, таких как синдром Клайнфельтера, синдром Каллмана, а также у мужчин с метаболическими (ожирение, сахарный диабет) или ятрогенными нарушениями, приводящими к снижению выработки андрогенов. Проект рекомендаций охватывает наибольший диапазон патологий, обусловливающих развитие гипогонадизма (дефицита тестостерона), и фокусируется на его клинических вариантах, которые составляют большую часть случаев гипогонадизма, наблюдающихся у мужчин. Авторы и рецензенты представляют собой междисциплинарную группу экспертов, состоящую из эндокринологов, андрологов, урологов — членов ОО «Российская ассоциация эндокринологов» и Межрегиональной ОО «Мужское и репродуктивное здоровье». Клинические рекомендации содержат самые надежные доказательства, доступные экспертам на момент создания. Однако рекомендации не могут заменить клинический опыт. Принимать решение о начале лечения, выбирать метод терапии или препарат для конкретных пациентов необходимо с учетом их индивидуальных особенностей.

Hypogonadism in males, defined as a decrease in serum testosterone levels in combination with characteristic symptoms and/or signs, can be observed with pathological changes in the testicles and/or pituitary gland, such as Klinefelter’s syndrome, Kallman’s syndrome, as well as in men with metabolic (obesity, diabetes mellitus) or iatrogenic disorders leading to a decrease in androgen production. The draft guidelines cover the extensive range of pathologies that cause hypogonadism development (testosterone deficiency) and focus on its clinical variants, which make up the majority of cases of hypogonadism observed in men. The authors and reviewers are an interdisciplinary group of experts, consisting of endocrinologists, andrologists, urologists - members of the «Russian Association of Endocrinologists» and «Men’s and Reproductive Health» public organizations.

Clinical guidelines contain the most reliable evidence available to experts at the time of writing. Nevertheless, recommendations cannot replace clinical experience, and deciding on the start of treatment, choosing a method of therapy, or a drug should always consider the individual characteristics of a specific patient.

гипогонадизммужчиныдефицит тестостеронатестостеронклинические рекомендацииHypogonadismmentestosterone deficiencytestosteroneclinical practice guidelinesReferencesWu FCW, Tajar A, Beynon JM, et al. Identification of Late-Onset Hypogonadism in Middle-Aged and Elderly Men. N Engl J Med. 2010;363(2):123-135. doi: https://doi.org/10.1056/NEJMoa0911101.Wu FCW, Tajar A, Beynon JM, et al. Identification of Late-Onset Hypogonadism in Middle-Aged and Elderly Men. N Engl J Med. 2010;363(2):123-135. doi: https://doi.org/10.1056/NEJMoa0911101.Tajar A, Huhtaniemi IT, O’Neill TW, et al. Characteristics of Androgen Deficiency in Late-Onset Hypogonadism: Results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab. 2012;97(5):1508-1516. doi: https://doi.org/10.1210/jc.2011-2513Tajar A, Huhtaniemi IT, O’Neill TW, et al. Characteristics of Androgen Deficiency in Late-Onset Hypogonadism: Results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab. 2012;97(5):1508-1516. doi: https://doi.org/10.1210/jc.2011-2513Agarwal PK, Singh P, Chowdhury S, et al. A study to evaluate the prevalence of hypogonadism in Indian males with Type-2 diabetes mellitus. Indian J Endocr Metab. 2017;21:64-70. doi: https://doi.org/10.4103/2230-8210.196008Agarwal PK, Singh P, Chowdhury S, et al. A study to evaluate the prevalence of hypogonadism in Indian males with Type-2 diabetes mellitus. Indian J Endocr Metab. 2017;21:64-70. doi: https://doi.org/10.4103/2230-8210.196008Beatrice A, Dutta D, Kumar M, et al. Testosterone levels and type 2 diabetes in men: current knowledge and clinical implications. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2014;7:481-486. doi: https://doi.org/10.2147/DMSO.S50777Beatrice A, Dutta D, Kumar M, et al. Testosterone levels and type 2 diabetes in men: current knowledge and clinical implications. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2014;7:481-486. doi: https://doi.org/10.2147/DMSO.S50777Ding EL, Song Y, Malik VS, Liu S. Sex Differences of Endogenous Sex Hormones and Risk of Type 2 Diabetes. JAMA. 2006;295(11):1288-1299. doi: https://doi.org/10.1001/jama.295.11.1288Ding EL, Song Y, Malik VS, Liu S. Sex Differences of Endogenous Sex Hormones and Risk of Type 2 Diabetes. JAMA. 2006;295(11):1288-1299. doi: https://doi.org/10.1001/jama.295.11.1288Rozhivanov RV. Endocrine disorders of sexual function in men. In: Dedov II, Mel’nochenko GA, editors. Rational pharmacotherapy of diseases of the endocrine system and metabolic disorders. 2nd ed. Moscow; 2013. P. 754-775. (In Russ.).Rozhivanov RV. Endocrine disorders of sexual function in men. In: Dedov II, Mel’nochenko GA, editors. Rational pharmacotherapy of diseases of the endocrine system and metabolic disorders. 2nd ed. Moscow; 2013. P. 754-775. (In Russ.).Grossmann M, Matsumoto AM. A Perspective on Middle-Aged and Older Men With Functional Hypogonadism: Focus on Holistic Management. J Clin Endocrinol Metab. 2017;102(3):1067-1075. doi: https://doi.org/10.1210/jc.2016-3580Grossmann M, Matsumoto AM. A Perspective on Middle-Aged and Older Men With Functional Hypogonadism: Focus on Holistic Management. J Clin Endocrinol Metab. 2017;102(3):1067-1075. doi: https://doi.org/10.1210/jc.2016-3580Zitzmann M, Faber S, Nieschlag E. Association of Specific Symptoms and Metabolic Risks with Serum Testosterone in Older Men. J Clin Endocrinol Metab. 2006;91(11):4335-4343. doi: https://doi.org/10.1210/jc.2006-0401Zitzmann M, Faber S, Nieschlag E. Association of Specific Symptoms and Metabolic Risks with Serum Testosterone in Older Men. J Clin Endocrinol Metab. 2006;91(11):4335-4343. doi: https://doi.org/10.1210/jc.2006-0401Tan WS, Ng CJ, Khoo E-M, et al. The triad of erectile dysfunction, testosterone deficiency syndrome and metabolic syndrome: findings from a multi-ethnic Asian men study (The Subang Men’s Health Study). Aging Male. 2011;14(4):231-236. doi: https://doi.org/10.3109/13685538.2011.597463Tan WS, Ng CJ, Khoo E-M, et al. The triad of erectile dysfunction, testosterone deficiency syndrome and metabolic syndrome: findings from a multi-ethnic Asian men study (The Subang Men’s Health Study). Aging Male. 2011;14(4):231-236. doi: https://doi.org/10.3109/13685538.2011.597463Tsujimura A, Miyagawa Y, Takezawa K, et al. Is Low Testosterone Concentration a Risk Factor for Metabolic Syndrome in Healthy Middle-aged Men? Urology. 2013;82(4):814-819. doi: https://doi.org/10.1016/j.urology.2013.06.023Tsujimura A, Miyagawa Y, Takezawa K, et al. Is Low Testosterone Concentration a Risk Factor for Metabolic Syndrome in Healthy Middle-aged Men? Urology. 2013;82(4):814-819. doi: https://doi.org/10.1016/j.urology.2013.06.023Ho C-H, Jaw F-S, Wu C-C, et al. The Prevalence and the Risk Factors of Testosterone Deficiency in Newly Diagnosed and Previously Known Type 2 Diabetic Men. J Sex Med. 2015;12(2):389-397. doi: https://doi.org/10.1111/jsm.12777Ho C-H, Jaw F-S, Wu C-C, et al. The Prevalence and the Risk Factors of Testosterone Deficiency in Newly Diagnosed and Previously Known Type 2 Diabetic Men. J Sex Med. 2015;12(2):389-397. doi: https://doi.org/10.1111/jsm.12777Cattabiani C, Basaria S, Ceda GP, et al. Relationship between testosterone deficiency and cardiovascular risk and mortality in adult men. J Endocrinol Invest. 2012;35(1):104-120. doi: https://doi.org/10.3275/8061Cattabiani C, Basaria S, Ceda GP, et al. Relationship between testosterone deficiency and cardiovascular risk and mortality in adult men. J Endocrinol Invest. 2012;35(1):104-120. doi: https://doi.org/10.3275/8061Lee DM, Tajar A, Pye SR, et al. Association of hypogonadism with vitamin D status: the European Male Ageing Study. European Journal of Endocrinology. 2011;166(1):77-85. doi: https://doi.org/10.1530/eje-11-0743Lee DM, Tajar A, Pye SR, et al. Association of hypogonadism with vitamin D status: the European Male Ageing Study. European Journal of Endocrinology. 2011;166(1):77-85. doi: https://doi.org/10.1530/eje-11-0743Reddy RG, Aung T, Karavitaki N, Wass JAH. Opioid induced hypogonadism. BMJ. 2010;341(aug31 1):c4462-c4462. doi: https://doi.org/10.1136/bmj.c4462Reddy RG, Aung T, Karavitaki N, Wass JAH. Opioid induced hypogonadism. BMJ. 2010;341(aug31 1):c4462-c4462. doi: https://doi.org/10.1136/bmj.c4462Rey RA, Grinspon RP. Normal male sexual differentiation and aetiology of disorders of sex development. Best Pract Res Clin Endocrinol Metab. 2011;25(2):221-238. doi: https://doi.org/10.1016/j.beem.2010.08.013Rey RA, Grinspon RP. Normal male sexual differentiation and aetiology of disorders of sex development. Best Pract Res Clin Endocrinol Metab. 2011;25(2):221-238. doi: https://doi.org/10.1016/j.beem.2010.08.013Isidori AM, Lenzi A. Risk factors for androgen decline in older males: lifestyle, chronic diseases and drugs. J Endocrinol Invest. 2005;28(3):14-22.Isidori AM, Lenzi A. Risk factors for androgen decline in older males: lifestyle, chronic diseases and drugs. J Endocrinol Invest. 2005;28(3):14-22.Bhasin S, Pencina M, Jasuja GK, et al. Reference Ranges for Testosterone in Men Generated Using Liquid Chromatography Tandem Mass Spectrometry in a Community-Based Sample of Healthy Nonobese Young Men in the Framingham Heart Study and Applied to Three Geographically Distinct Cohorts. J Clin Endocrinol Metab. 2011;96(8):2430-2439. doi: https://doi.org/10.1210/jc.2010-3012Bhasin S, Pencina M, Jasuja GK, et al. Reference Ranges for Testosterone in Men Generated Using Liquid Chromatography Tandem Mass Spectrometry in a Community-Based Sample of Healthy Nonobese Young Men in the Framingham Heart Study and Applied to Three Geographically Distinct Cohorts. J Clin Endocrinol Metab. 2011;96(8):2430-2439. doi: https://doi.org/10.1210/jc.2010-3012Vesper HW, Bhasin S, Wang C, et al. Interlaboratory comparison study of serum total testoserone measurements performed by mass spectrometry methods. Steroids. 2009;74(6):498-503. doi: https://doi.org/10.1016/j.steroids.2009.01.004Vesper HW, Bhasin S, Wang C, et al. Interlaboratory comparison study of serum total testoserone measurements performed by mass spectrometry methods. Steroids. 2009;74(6):498-503. doi: https://doi.org/10.1016/j.steroids.2009.01.004Wittert G, Bracken K, Robledo KP, et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes Endocrinol. 2021;9(1):32-45. doi: https://doi.org/10.1016/S2213-8587(20)30367-3Wittert G, Bracken K, Robledo KP, et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes Endocrinol. 2021;9(1):32-45. doi: https://doi.org/10.1016/S2213-8587(20)30367-3Tsertsvadze A, Fink HA, Yazdi F, et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: A systematic review and meta-analysis. Ann Intern Med. 2009;151:650-661. doi: https://doi.org/10.1059/0003-4819-151-9-200911030-00150Tsertsvadze A, Fink HA, Yazdi F, et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: A systematic review and meta-analysis. Ann Intern Med. 2009;151:650-661. doi: https://doi.org/10.1059/0003-4819-151-9-200911030-00150Rozhivanov RV, Kurbatov DG, Kravtsova NS. Differential and diagnostic, predictive and therapeutic value of test with clomifene in men with a Hypogonadizm. Problems of Endocrinology. 2016;62(1):35-37. (In Russ.). doi: https://doi.org/10.14341/probl201662135-37Rozhivanov RV, Kurbatov DG, Kravtsova NS. Differential and diagnostic, predictive and therapeutic value of test with clomifene in men with a Hypogonadizm. Problems of Endocrinology. 2016;62(1):35-37. (In Russ.). doi: https://doi.org/10.14341/probl201662135-37Vermeulen A. Hormonal cut-offs of partial androgen deficiency: a survey of androgen assays. J Endocrinol Invest. 2005;28(3):28-31.Vermeulen A. Hormonal cut-offs of partial androgen deficiency: a survey of androgen assays. J Endocrinol Invest. 2005;28(3):28-31.Bremner AP, Feddema P, Leedman PJ, et al. Age-Related Changes in Thyroid Function: A Longitudinal Study of a Community-Based Cohort. J Clin Endocr Metab. 2012;97(5):1554-1562. doi: https://doi.org/10.1210/jc.2011-3020Bremner AP, Feddema P, Leedman PJ, et al. Age-Related Changes in Thyroid Function: A Longitudinal Study of a Community-Based Cohort. J Clin Endocr Metab. 2012;97(5):1554-1562. doi: https://doi.org/10.1210/jc.2011-3020Rozhivanov RV. Effective therapy and errors in treatment of endocrine disorders in andrology. In: Dedov II, Melnichenko GA, editors. Endocrinology. Pharmacotherapy without errors. Moscow; 2013. P. 615-625. (in Russ.).Rozhivanov RV. Effective therapy and errors in treatment of endocrine disorders in andrology. In: Dedov II, Melnichenko GA, editors. Endocrinology. Pharmacotherapy without errors. Moscow; 2013. P. 615-625. (in Russ.).Rozhivanov RV, Shurdumova BO, Parfenova NS, Savel’eva LV. Kompleksnyy podkhod k lecheniyu ozhireniyai metabolicheskogo sindroma u muzhchin. Obesity and metabolism. 2009;6(4):38-41. (In Russ.). doi: https://doi.org/10.14341/2071-8713-4877Rozhivanov RV, Shurdumova BO, Parfenova NS, Savel’eva LV. Kompleksnyy podkhod k lecheniyu ozhireniyai metabolicheskogo sindroma u muzhchin. Obesity and metabolism. 2009;6(4):38-41. (In Russ.). doi: https://doi.org/10.14341/2071-8713-4877Corona G, Vignozzi L, Sforza A, et al. Obesity and late-onset hypogonadism. Mol Cell Endocrinol. 2015;418:120-133. doi: https://doi.org/10.1016/j.mce.2015.06.031Corona G, Vignozzi L, Sforza A, et al. Obesity and late-onset hypogonadism. Mol Cell Endocrinol. 2015;418:120-133. doi: https://doi.org/10.1016/j.mce.2015.06.031Dedov II, Shestakova MV, Mayorov AYu, et al. Standards of specialized diabetes care. Diabetes Mellitus. 2019;22(S1):1-144 (In Russ.). doi: https://doi.org/10.14341/DM221S1Dedov II, Shestakova MV, Mayorov AYu, et al. Standards of specialized diabetes care. Diabetes Mellitus. 2019;22(S1):1-144 (In Russ.). doi: https://doi.org/10.14341/DM221S1Tracz MJ, Sideras K, Boloña ER, et al. Testosterone Use in Men and Its Effects on Bone Health. A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. J Clin Endocrinol Metab. 2006;91(6):2011-2016. doi: https://doi.org/10.1210/jc.2006-0036Tracz MJ, Sideras K, Boloña ER, et al. Testosterone Use in Men and Its Effects on Bone Health. A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. J Clin Endocrinol Metab. 2006;91(6):2011-2016. doi: https://doi.org/10.1210/jc.2006-0036Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf). 2005;63(3):280-293. doi: https://doi.org/10.1111/j.1365-2265.2005.02339.xIsidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf). 2005;63(3):280-293. doi: https://doi.org/10.1111/j.1365-2265.2005.02339.xBasaria S, Lakshman KM. Safety and efficacy of testosterone gel in the treatment of male hypogonadism. Clin Interv Aging. 2009;4:397-412. doi: https://doi.org/10.2147/CIA.S4466Basaria S, Lakshman KM. Safety and efficacy of testosterone gel in the treatment of male hypogonadism. Clin Interv Aging. 2009;4:397-412. doi: https://doi.org/10.2147/CIA.S4466Fernandez-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(6):2560-2575. doi: https://doi.org/10.1210/jc.2009-2575Fernandez-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(6):2560-2575. doi: https://doi.org/10.1210/jc.2009-2575Calof OM, Singh AB, Lee ML, et al. Adverse Events Associated With Testosterone Replacement in Middle-Aged and Older Men: A Meta-Analysis of Randomized, Placebo-Controlled Trials. Journals Gerontol Ser A Biol Sci Med Sci. 2005;60(11):1451-1457. doi: https://doi.org/10.1093/gerona/60.11.1451Calof OM, Singh AB, Lee ML, et al. Adverse Events Associated With Testosterone Replacement in Middle-Aged and Older Men: A Meta-Analysis of Randomized, Placebo-Controlled Trials. Journals Gerontol Ser A Biol Sci Med Sci. 2005;60(11):1451-1457. doi: https://doi.org/10.1093/gerona/60.11.1451Basaria S, Coviello AD, Travison TG, et al. Adverse Events Associated with Testosterone Administration. N Engl J Med. 2010;363(2):109-122. doi: https://doi.org/10.1056/NEJMoa1000485Basaria S, Coviello AD, Travison TG, et al. Adverse Events Associated with Testosterone Administration. N Engl J Med. 2010;363(2):109-122. doi: https://doi.org/10.1056/NEJMoa1000485Johansen Taber KA, Morisy LR, Osbahr AJ 3rd, et al. Male breast cancer: risk factors, diagnosis, and management (review). Oncol Rep. 2010;24(5):1115-1120. doi: https://doi.org/10.3892/or_00000962Johansen Taber KA, Morisy LR, Osbahr AJ 3rd, et al. Male breast cancer: risk factors, diagnosis, and management (review). Oncol Rep. 2010;24(5):1115-1120. doi: https://doi.org/10.3892/or_00000962Shabsigh R, Crawford ED, Nehra A, Slawin KM. Testosterone therapy in hypogonadal men and potential prostate cancer risk: A systematic review. Int J Impot Res. 2009;21(1):9-23. doi: https://doi.org/10.1038/ijir.2008.31Shabsigh R, Crawford ED, Nehra A, Slawin KM. Testosterone therapy in hypogonadal men and potential prostate cancer risk: A systematic review. Int J Impot Res. 2009;21(1):9-23. doi: https://doi.org/10.1038/ijir.2008.31Marks LS, Mazer NA, Mostaghel E, et al. Effect of Testosterone Replacement Therapy on Prostate Tissue in Men With Late-Onset Hypogonadism. JAMA. 2006;296(19):2351. doi: https://doi.org/10.1001/jama.296.19.2351Marks LS, Mazer NA, Mostaghel E, et al. Effect of Testosterone Replacement Therapy on Prostate Tissue in Men With Late-Onset Hypogonadism. JAMA. 2006;296(19):2351. doi: https://doi.org/10.1001/jama.296.19.2351Medras M, Filus A, Jozkow P, et al. Breast cancer and long-term hormonal treatment of male hypogonadism. Breast Cancer Res Treat. 2006;96(3):263-265. doi: https://doi.org/10.1007/s10549-005-9074-yMedras M, Filus A, Jozkow P, et al. Breast cancer and long-term hormonal treatment of male hypogonadism. Breast Cancer Res Treat. 2006;96(3):263-265. doi: https://doi.org/10.1007/s10549-005-9074-yOhlander SJ, Lindgren MC, Lipshultz LI. Testosterone and Male Infertility. Urol Clin North Am. 2016;43(2):195-202. doi: https://doi.org/10.1016/j.ucl.2016.01.006Ohlander SJ, Lindgren MC, Lipshultz LI. Testosterone and Male Infertility. Urol Clin North Am. 2016;43(2):195-202. doi: https://doi.org/10.1016/j.ucl.2016.01.006Corona G, Maseroli E, Rastrelli G, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf. 2014;13(10):1327-1351. doi: https://doi.org/10.1517/14740338.2014.950653Corona G, Maseroli E, Rastrelli G, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf. 2014;13(10):1327-1351. doi: https://doi.org/10.1517/14740338.2014.950653Giagulli VA, Triggiani V, Corona G, et al. Evidence-based medicine update on testosterone replacement therapy (TRT) in male hypogonadism: focus on new formulations. Curr Pharm Des. 2011;17(15):1500-1511. doi: https://doi.org/10.2174/138161211796197160Giagulli VA, Triggiani V, Corona G, et al. Evidence-based medicine update on testosterone replacement therapy (TRT) in male hypogonadism: focus on new formulations. Curr Pharm Des. 2011;17(15):1500-1511. doi: https://doi.org/10.2174/138161211796197160Moon DG, Park MG, Lee SW, et al. The Efficacy and Safety of Testosterone Undecanoate (Nebido®) in Testosterone Deficiency Syndrome in Korean: A Multicenter Prospective Study. The Journal of Sexual Medicine. 2010;7(6):2253-2260. doi: https://doi.org/10.1111/j.1743-6109.2010.01765.xMoon DG, Park MG, Lee SW, et al. The Efficacy and Safety of Testosterone Undecanoate (Nebido®) in Testosterone Deficiency Syndrome in Korean: A Multicenter Prospective Study. The Journal of Sexual Medicine. 2010;7(6):2253-2260. doi: https://doi.org/10.1111/j.1743-6109.2010.01765.xSaad F, Aversa A, Isidori AM, et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. European Journal of Endocrinology. 2011;165(5):675-685. doi: https://doi.org/10.1530/eje-11-0221Saad F, Aversa A, Isidori AM, et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. European Journal of Endocrinology. 2011;165(5):675-685. doi: https://doi.org/10.1530/eje-11-0221McMullin MF, Bareford D, Campbell P, et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol. 2005;130(2):174-195. doi: https://doi.org/10.1111/j.1365-2141.2005.05535.xMcMullin MF, Bareford D, Campbell P, et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol. 2005;130(2):174-195. doi: https://doi.org/10.1111/j.1365-2141.2005.05535.xРоживанов Р.В., Курбатов Д.Г. Гематологические и урологические аспекты безопасности заместительной андрогенной терапии препаратом тестостерона ундеканоата пролонгированного действия у пациентов с гипогонадизмом // Проблемы эндокринологии. — 2009. — Т. 55. — №6. — С. 31-35. doi: https://doi.org/10.14341/probl200955631-35Rozhivanov RV, Kurbatov DG. Hematological and urological aspects of the safety of androgen substitution therapy using long-acting testosterone undecanoate in patients with hypogonadism. Problems of Endocrinology. 2009;55(6):31-35. (In Russ.). doi: https://doi.org/10.14341/probl200955631-35Kardoust Parizi M, Abufaraj M, Fajkovic H, et al. Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: A systematic literature review and meta-analysis. Urol Oncol Semin Orig Investig. 2019;37(10):637-646. doi: https://doi.org/10.1016/j.urolonc.2019.06.007Kardoust Parizi M, Abufaraj M, Fajkovic H, et al. Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: A systematic literature review and meta-analysis. Urol Oncol Semin Orig Investig. 2019;37(10):637-646. doi: https://doi.org/10.1016/j.urolonc.2019.06.007Morgentaler A, Morales A. Should Hypogonadal Men With Prostate Cancer Receive Testosterone? J Urol. 2010;184(4):1257-1260. doi: https://doi.org/10.1016/j.juro.2010.07.010Morgentaler A, Morales A. Should Hypogonadal Men With Prostate Cancer Receive Testosterone? J Urol. 2010;184(4):1257-1260. doi: https://doi.org/10.1016/j.juro.2010.07.010Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 2004;172(3):920-922. doi: https://doi.org/10.1097/01.ju.0000136269.10161.32Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 2004;172(3):920-922. doi: https://doi.org/10.1097/01.ju.0000136269.10161.32Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007;109(3):536-541. doi: https://doi.org/10.1002/cncr.22438Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007;109(3):536-541. doi: https://doi.org/10.1002/cncr.22438

The authors declare that there are no conflicts of interest present.